Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial

Fig. 2

Primary and secondary outcomes with FCM vs placebo in patients with and without diabetes. mITT population analyzed. All models adjusted for covariates: sex, age, HF etiology, HF duration, country, and diabetes status at baseline, and diabetes at baseline × treatment. N = 1108 for all patients. Respective n-values in patients with and without diabetes at baseline were 231 and 327 for FCM and 244 and 306 for placebo. aAnnualized event rate per 100 patient-years and annualized event RR were both analyzed using a negative binomial model. bFCM vs placebo. cHR for treatment difference analyzed using Cox regression model. dEvent refers to days off work. CI confidence interval, CV cardiovascular, FCM ferric carboxymaltose, HF heart failure, HR hazard ratio, mITT modified intention-to-treat, RR rate ratio

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840